1. Home
  2. CRNX vs NG Comparison

CRNX vs NG Comparison

Compare CRNX & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$38.65

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Novagold Resources Inc.

NG

Novagold Resources Inc.

HOLD

Current Price

$9.75

Market Cap

3.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
NG
Founded
2008
1984
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.7B
IPO Year
2018
2002

Fundamental Metrics

Financial Performance
Metric
CRNX
NG
Price
$38.65
$9.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
6
Target Price
$76.63
$12.22
AVG Volume (30 Days)
1.1M
3.8M
Earning Date
05-07-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
N/A
Revenue Next Year
$184.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$2.84
52 Week High
$57.99
$14.40

Technical Indicators

Market Signals
Indicator
CRNX
NG
Relative Strength Index (RSI) 50.88 53.53
Support Level $33.19 $9.13
Resistance Level $45.32 $10.44
Average True Range (ATR) 1.56 0.56
MACD 0.74 0.21
Stochastic Oscillator 74.42 97.95

Price Performance

Historical Comparison
CRNX
NG

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About NG Novagold Resources Inc.

Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.

Share on Social Networks: